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Objectives: The present study was designed to estimate the prevalence of
dyslipidemia and hypertension based on the National Cholesterol Educational
Programme Adult Treatment Panel III definition of metabolic syndrome (MetS).
The study also focuses on prevalence for MetS with respect to the duration of
disease in GwalioreChambal region of Madhya Pradesh, India.
Methods: Type 2 diabetic patients (n Z 700) were selected from a cross-
sectional study that is regularly being conducted in the School of Studies in
Biochemistry, Jiwaji University Gwalior, India. The period of our study was from
January 2007 to October 2009. Dyslipidemia and hypertension were determined
in type 2 diabetic patients with MetS as per National Cholesterol Educational
Programme Adult Treatment Panel III criteria.
Results: The mean age of the study population was 54  9.3 years with 504 (72%)
males and 196 (28%) females. The prevalence of MetS increased with increased
duration of diabetes in females; however, almost constant prevalence was seen in
the males. Notable increase in the dyslipidemia (64.1%) and hypertension (49%) in
type 2 diabetic patients were seen. The steep increase in dyslipidemia and hy-
pertension could be the reason for the growing prevalence of diabetes worldwide.
The study also noted a close association between age and occurrence of MetS.
Conclusion: Individual variable of MetS appears to be highly rampant in diabetic
population. Despite treatment, almost half of patients still met the criteria for
MetS. Effective treatment of MetS components is required to reduce cardiovas-
cular risk in diabetes mellitus hence accurate and early diagnosis to induce
effective treatment of MetS in Indian population will be pivotal in the prevention
of cardiovascular disease and type 2 diabetes.ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
0) which permits unrestricted non-commercial use, distribution, and reproduction in any
roperly cited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
170 D. Yadav, et al1. Introduction
Metabolic syndrome (MetS) is a group of anthropo-
logical and biochemical abnormalities that confers a
greater risk factor for type 2 diabetesmellitus (T2DM) and
cardiovascular disease (CVD) [1]. Gerald Reaven [2]
introduced the concept of the syndrome in 1988. Later,
this constellation of CVD risk factors was given a number
of names, such as Syndrome X, dysmetabolic syndrome,
insulin resistance syndrome, and the deadly quartet [3,4].
Dyslipidemia and hypertension are classical constituents
of MetS. The underlying mechanism for development of
hypertension and hyperlipidemia in the MetS has been
clearly established [5,6]. Insulin resistance and obesity
play a central role in causing hypertension and dyslipide-
mia, and further predisposes toMetS [7,8]. Cuspidi et al [9]
and Schillaci et al [10] observed the prevalence ofMetS in
almost one third of the hypertensive patients observed in
their studies. In obese individuals, the prevalence of MetS
is about 40% [11]. Therefore, high blood pressure and
dyslipidemia were included for efficiently diagnosing
MetS in the National Cholesterol Educational Programme
Adult Treatment Panel III (NCEP-ATPIII). Currently, the
rate of MetS is increasing globally, even in the general
population [12]. The recent increase in cardiovascular
mortality and morbidity in diabetic patients [13] offer the
ample time to apply these criteria for predicting the risk of
CVD in these populations [14]. Macrovascular compli-
cations are indeed the most common cause of morbidity
and mortality in patients with T2DM [15].
The study follows ATP III criteria for predicting the
occurrence of MetS. The definition is an effort to make
the criteria more user-friendly for medical practitioners.
Unlike the other definitions, no single risk factor is
required. Any three of five factors [increased waist
circumference, high triglyceride, low high-density li-
poprotein-cholesterol (HDL-C), elevated blood pressure,
and high fasting plasma glucose] are sufficient to
establish the diagnosis. The primary goal of NCEP is to
identify individuals at increased risk of CVD [16].
Recently, the NCEP-ATPIII definitions for MetS were
renewed to include the new cut-off waist circumference
and fasting glucose for the Asia-Pacific Region [17].
The present study was performed to determine the
prevalence of dyslipidemia and hypertension in T2DM
patients with MetS. Accurate information regarding the
prevalence of dyslipidemia and hypertension in studied
populations will predict the exact threat for a particular
disorder and aid in the early diagnosis and possible
prevention of CVD.2. Materials and methods
2.1. Study participants
T2DM patients were selected from a weekly diabetes
camp organized in the School of Biochemistry, JiwajiUniversity Gwalior, India. The period of study was be-
tween January 2007 and October 2009. The cross-
sectional study included 504 males and 196 females,
with a mean age of 55  9.15 years and
53.1  9.6 years, respectively. Information about par-
ticipants’ age, sex, monthly income, life style, family
history of diabetes, and prior diseases/disorders history
were recorded. Before registering for the study written
consent was obtained from the participants, expressing
their willingness to participate in the study. Ethical
approval was obtained from the Jiwaji University
Gwalior prior to commencement of the study. The study
design and experimental protocols were approved by the
Institutional Human Ethics Committee. Selected
anthropometrical parameters such as height, weight, and
waist circumferences were measured with the partici-
pant being barefooted and dressed lightly. The abdom-
inal (waist) circumference was measured at the end of
expiration, by wrapping a tape at the level of the um-
bilicus. Body mass index (BMI) was calculated as kg/
m2. Blood pressure (BP) was measured with a special
precaution to reduce the variation of BP value with
resting values; individuals were requested to take
10 minutes rest prior to measuring the BP with a stan-
dard electronic BP measuring instrument.
2.2. Blood sample collection
Fasting blood samples were collected in EDTA vial
and plasma was separated by centrifuging the blood
samples at 8000 rpm for 10e15 minutes following
which the fasting blood glucose was measured by
glucose oxidaseeperoxidase method using a kit (Mon-
ozyme India Limited, Ahmadabad, India) [18]. Total
cholesterol, triglyceride, and HDL-C levels were esti-
mated by spectrophotometric assays employing
commercially available kits [19e21]. Low- and very-
low-density lipoproteins were calculated from Freide-
wald’s formula.
2.3. Definitions for diagnosing dyslipidemia and
hypertension
For diagnosing of dyslipidemia, triglyceride and
HDL-C level were used as parameters. Plasma tri-
glycerides (150 mg/dL); HDL-C (<40 mg/dL for
males and <50 mg/dL for females); and hypertension
(130/85 mmHg) as listed in NCEP guidelines [16].
2.4. Statistical analysis
Data are expressed as mean  standard deviation.
Student t test was used for deducting the mean of the
two groups. A p value of <0.05 was considered as
statistically significant. The age specific distribution of
the prevalence of MetS were calculated separately for
males and females described in percentages. Data were
analyzed employing Sigma Stat, statistical software,
version 1.0 (Jandel Corporation, San Rafael, CA, U.S.A)
for descriptive statistics.
Prevalence of dyslipidemia and hypertension 1713. Results
The study shows that the prevalence of MetS was
41% in males and 58% in females. Table 1 represents
the frequency of MetS, hypertension, and dyslipidemia
in the selected population stratified by sex. Hypertension
and dyslipidemia were frequently observed in T2DM
populations involved in the study. Out of 504 males and
196 females, hypertension was observed as 55.2% and
42.9%, respectively, in the total population, which was
found to be statistically significant (p < 0.001). The
prevalence of dyslipidemia in T2DM population were
56.3% and 72% in males and females, respectively.
The mean age of the studied population was
calculated to be 54 years. The duration of diabetes in
the study participants was 1e20 years with a mean of
6 years. Table 2 depicts the clinical data representing
the anthropometrical and biochemical parameters of
the patients categorized by the duration of disease. The
prevalence of MetS was evaluated in patients with a
different duration of disease (0e5 years, 6e10 years,
> 10 years), in relation to age, fasting, BMI, systolic
BP, diastolic BP, pulse, cholesterol, triglyceride, and
HDL-C. In males, the prevalence was 37% under
0e5 years. Prevalence of MetS in T2DM patients with
a duration of disease 6e10 years and >10 years were
39.4% and 39%, respectively. In females, the preva-
lence was 53% with duration of the disease <5 years
and increased to 56% and 68% in 6e10 years, and
>10 years of disease duration, respectively. The
overall prevalence of MetS in T2DM patients studied
was significantly (p < 0.001) higher in females
(58.2%) than in males (41%; Tables 1 and 2). The
occurrence of MetS female patients with a lesser
duration of disease exhibited lower prevalence when
compared with those females with >10 years of dis-
ease duration but the same was not found to be
consistent in males. The prevalence in females
increased from 53% to 68% with an increase in the
duration of disease from <5 years to >10 years.Table 1. Frequency of metabolic syndrome, hypertension, and d
Male (n Z 504), n (%) Fe
Metabolic syndrome
Absent 297 (59)
Present 207 (41)
Hypertensionb
Absent 226 (44.8)
Present 278 (55.2)
Dyslipidemiac
Absent 220 (43.6)
Present 284 (56.3)
aDifference is the difference in the mean or percentage of the variable between
diastolic blood pressure 85 mmHg or use of oral antihypertensive medication
(0.9 mmol/L) in men or < 50 mg/dL (1.0 mmol/L) in women. *p < 0.05. **p <The association between age group and occurrence of
MetS in type 2 diabetic patients is represented in Table
3. The patients were grouped into five categories based
on their age (25e34 years, 35e44 years, 45e54 years,
55e64 years, and <65 years). Coded values in the
dataset were given with respect to each age group. The
patients with MetS were coded as “yes” and those
without MetS were coded “no”. The odd ratio for the
MetS was seen to increase with age in all populations
except the elderly. It was noted that in the age group of
55e64 years, the odds are almost five times higher for
the MetS compared with the baseline.
Table 4 shows the percentage of individual variables
in the MetS patients categorized by NCEP-ATP III in
males and females. The total number of MetS patients in
the studied population was 321, of which 207 were
males and 114 were females. The elevated waist
circumference (>102 cm (M) >88 cm (F)) among MetS
was found to be 38%, of which 22%, were males and
68.4% females. Out of all MetS patients 77% were hy-
pertensive, of which 85% were males and 64% were
females. The percentage of high triglyceride and low
HDL-C levels in the total MetS population was 49% and
62% respectively; in males this was 49% and 58%, and
50% and 67.5% in females, respectively.
Prevalence rate of the individual components of
MetS at baseline variables are shown in Table 5. Out of
700 patients 504 were males. The occurrence of MetS
was higher in females with 58% frequency. The crude
relative prevalence of MetS in the female patients was
found to be statistically significant (p < 0.05) when
compared with the male population. The influence of the
potential factors of dyslipidemia and hypertension in the
MetS definition was determined by univariate analysis.
The fasting blood glucose was classified according to
the level as 111e150 mg/dL, 151e190 mg/dL, and
191 mg/dL, with crude relative prevalence of 2.5,
2.29, and 2.22 respectively with an observed (p  0.001)
significance. The systolic blood pressure level was
130e149 mmHg and 150e169 mmHg with significantyslipidemia in the studied population with respect to gender.
male (n Z 196), n (%) Difference (95% CI)a
82 (41.8)
114 (58.2) p < 0.05
112 (57.1)
84 (42.9) 7.8 (3.739, 11.861)**
55 (28)
141 (72) 9 (5.34, 23.34)
males and females; bHypertension: systolic blood pressure 130 mmHg or
; cDyslipidemia: triglyceride 150 mg/dL or HDL cholesterol <40 mg/dL
0.001.
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172 D. Yadav, et al(p  0.001) crude relative prevalence of 2.85 and 2.91.
The systolic BP  170 mmHg had crude relative
prevalence of 2.49 with p  0.01, which indicates
strong association of systolic BP with MetS. Similar
results were observed in diastolic BP. The triglyceride
levels 150e299 mg/dL and 300 mg/dL illustrated a
crude relative prevalence of 2.10 and 1.84 with a sig-
nificance of p  0.001 and p  0.05, respectively.
Significance of p  0.01 and p  0.05 was also
observed in HDL-C level in the range 40e49 mg/dL
and >50 mg/dL, respectively.4. Discussion
The aim of the present study was to focus on the
prevalence of dyslipidemia and hypertension in studied
population as per the definition of NCEP-ATPIII
criteria in an urban setting. The study included T2DM
patients who attended the diabetes camp in 2007e2009
(every weekend) organized by Jiwaji University Gwa-
lior. This study elucidates the individual and clustering
of cardiovascular risk factors, like hypertension,
obesity, including the MetS in T2DM. Cardiovascular
risk factors in T2DM are the common causes of
morbidity and mortality in patients with diabetes. In a
developing nation such as India, limited information is
available about the prevalence of dyslipidemia and
hypertension in T2DM patients.
From this study we have found that the prevalence
of MetS in the studied population was 45.8% based on
NCEP-ATPIII criteria [22]. We reported hypertension
were significantly prevalent (p < 0.001) in 55.2% of
males and in 42.9% of females. The high prevalence of
MetS was dependent on the duration of disease in both
the sexes. The prevalence was increased from 58.2% to
68% with an increase in the duration of disease in fe-
males from <5 years to >10 years (Table 2). The
present study also observed that the odds ratio for MetS
increased with an increase in age in the diabetic pop-
ulation (Table 3). The association of age and the
development of MetS in the normal and diabetic pop-
ulation has already been observed in several of studies
[23e25].
In this study, 50% of the participants had high sys-
tolic and diastolic BP, and low HDL-C (Table 4).
Prevalence rates of individual components of MetS by
baseline variables are shown in Table 5. The table
shows, that on moving from baseline to higher levels in
systolic as well as diastolic BP, triglyceride, and HDL-
C, the crude relative prevalence in each parameter has
increased significantly. The present study corroborates
with the observations of previous studies [26e29].
Over half of the participants had hypertension and
dyslipidemia, which is in accordance with the previ-
ously reported studies [23,30]. We found an overall
prevalence of dyslipidemia and hypertension in the
Table 3. The association between age group and occurrence of metabolic syndrome in type 2 diabetic patients.
Age group (y) Coded value in dataseta
Metabolic syndrome
Odds of syndrome
Odds ratio compared to
baseline groupYes No
25e34 0 2 9 0.22 1
35e44 1 35 49 0.71 3.27
45e54 2 121 148 0.81 3.68
55e64 3 106 100 1.06 4.81
>65 4 57 73 0.78 3.5
aCoded values in dataset were given with respect to each age group.
Prevalence of dyslipidemia and hypertension 173studied population as 64.1% and 49%, respectively
(Table 1). Hypertension and dyslipidemia were found to
be significantly more common among females with
MetS (Table 4).
Our study also provides the first estimate of the
prevalence of dyslipidemia and hypertension in an urban
population of T2DM patients attributed to the lower cut-
off for waist circumference and higher cut-off for HDL-Table 4. Frequency of high waist circumference, high blood pre
cholesterol (HDL-C) in metabolic syndrome patients
Adult Treatment Panel III criteria.
Characteristics
Metabolic syndrome 321
High waist circumference 123 (38)
High blood pressure 248 (77)
Elevated triglyceride 158 (49)
Low HDL-C 98 (62)
Data are presented as n (%).
Table 5. Prevalence rates of systolic and diastolic blood pressu
Variables Numbers Metabolic syndrome
Systolic BP
<130 359 87
130e149 221 153
150e169 82 58
170 38 23
Diastolic BP
<80 459 154
80e90 162 104
90 79 63
Triglyceride
<150 473 161
150e299 192 138
300 35 22
HDL-C
>40 254 150
40e49 171 60
50 275 111
aRelative prevalence (with 95% confidence interval). Hypertension: systolic bloo
oral antihypertensive medication. Dyslipidemia: triglyceride 150 mg/dL or high
women. *p < 0.05. **p < 0.01. ***p < 0.001.C in females as compared to males. Therefore, more
females were classified as having high waist circum-
ference or low HDL-C. Males, by contrast, were likely
to have hypertension. The overall prevalence of hyper-
tension among the studied population was 49% and was
different between males and females (Table 1). This was
not consistent with the study reported by Kengne et al
[31], who observed an equal prevalence among malesssure, elevated triglyceride, and low high density lipoprotein
diagnosed by National Cholesterol Educational Programme
Males Females
207 114
45 (22) 78 (68.4)
175 (85) 73(64)
101 (49) 57(50)
121 (58) 77 (67.5)
re (BP) and dyslipidemic parameters by baseline variables.a
Prevalence (%)
Crude relative prevalence
(95% CI)
24.2 1
69 2.85 (2.06, 3.95)***
70.7 2.91 (1.89, 4.47)***
60.5 2.49 (1.34, 4.54)**
34 1
64 1.91 (1.38, 2.62)***
80 2.37 (1.59, 3.52)***
34 1
72 2.10 (1.57, 2.82)***
63 1.84 (0.99, 3.34)*
59 1
35 0.59 (0.40, 0.86)**
40.3 0.68 (0.501, 0.931)*
d pressure 130 mmHg or diastolic blood pressure 85 mmHg or use of
density lipoprotein-cholesterol (HDL-C)< 0.9 mM in men or < 1.0 mM in
174 D. Yadav, et aland females. Moreover, in our study, hypertension
observed in males was higher than that in females,
which is in accordance with Marjani and Shirafkan’s
[32] observations in Gorgan T2DM patients. The overall
prevalence of dyslipidemia in our recruited population
was 64.1%, which was higher than that reported in the
study by Janghorbani and Amini [33] in a follow-up
T2DM population.
The study concludes that hypertension in males was
higher than in females of T2DM populations whereas
dyslipidemia was more predominant in females. The
cross-sectional study by Janghorbani and Amini [34] in
T2DM report significantly higher prevalence of both
hypertension and dyslipidemia in females. The preva-
lence of high waist circumference, high BP, and low
HDL-C in MetS group of diabetic patients was 38%,
77%, and 62%, respectively (Table 4), indicating high
risk factors for cardiovascular morbidity and mortality
in the future. Our study on the prevalence of dyslipi-
demia and hypertension in MetS correlates with the
study on the Nigerian population conducted by Osuji
et al [35]. In the MetS population, the current study
found 55.5% of patients to be dyslipidemic (Table 4)
whereas Janghorbani and Amini [33] reported only
36.6% of dyslipidemic patients in one of the prospective
follow-up study.
The prevalence of hypertension in MetS patients in
our study population was 77%, which is higher than in
those studies reported earlier on MetS patients [34]. In
adults with T2DM, the presence of MetS was associated
with a fivefold increase in CV risk independent of age,
sex, smoking status, and glycated hemoglobin (HbA1c)
[36]. Therefore, it is necessary that assertive therapy be
aimed at controlling hyperglycemia, dyslipidemia, and
hypertension. Accurate information regarding the prev-
alence of dyslipidemia and hypertension associated risk
factors in people with T2DM plays a significant role for
the prevention or delaying of fulminant complications in
the near future.
The limitations of our study include our experimental
design, which is cross-sectional; therefore, our findings
may not clearly show the involvement of dyslipidemia
and hypertension. The time taken for selecting the pa-
tients was about 3 years and the test population was
restricted to a lower number of people. In spite of this
our results suggest that the severity of diabetes relates
with the duration of disease, age, and the entire MetS
variables are important in defining the risk of macro-
vascular diseases in diabetic patients. Periodic assess-
ment of patients with diabetes should include the
calculation of the MetS score so that those who have
particularly high cardiovascular risk can be targeted for
dyslipidemia and hypertension in forceful risk man-
agement. Overall, dyslipidemia and hypertension diag-
nosed with NCEP-ATPIII criteria can serve as a simple
clinical approach to identify persons at risk for the
timely intervention directed to reduce both CVD andT2DM. Treatment for each variable is needed to reduce
the risk factor for CVD. Knowledge of the variables
influencing the development of the syndrome can be
utilized in interventions that could favorably alter its
prevalence and therefore reduce the aggressiveness of
the disease.Conflicts of interest
All contributing authors declare no conflicts of
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